375 related articles for article (PubMed ID: 15711268)
1. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.
Shen S; Lepor H; Yaffee R; Taneja SS
J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268
[TBL] [Abstract][Full Text] [Related]
2. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.
Haese A; Huland E; Graefen M; Hammerer P; Noldus J; Huland H
J Urol; 1999 Apr; 161(4):1206-11. PubMed ID: 10081870
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy.
Patel R; Lepor H; Thiel RP; Taneja SS
Urology; 2005 May; 65(5):942-6. PubMed ID: 15882728
[TBL] [Abstract][Full Text] [Related]
4. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival.
Doherty AP; Bower M; Smith GL; Miano R; Mannion EM; Mitchell H; Christmas TJ
Br J Cancer; 2000 Dec; 83(11):1432-6. PubMed ID: 11076649
[TBL] [Abstract][Full Text] [Related]
5. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH.
King CR; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
Urology; 2007 Apr; 69(4):732-7. PubMed ID: 17445660
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy.
Nakamura M; Hasumi H; Miyoshi Y; Sugiura S; Fujinami K; Yao M; Kubota Y; Uemura H
Int J Urol; 2005 Dec; 12(12):1050-4. PubMed ID: 16409609
[TBL] [Abstract][Full Text] [Related]
7. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L.
Yu H; Diamandis EP; Wong PY; Nam R; Trachtenberg J
J Urol; 1997 Mar; 157(3):913-8. PubMed ID: 9072598
[TBL] [Abstract][Full Text] [Related]
8. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
9. Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database.
Chang SL; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
Urology; 2010 Feb; 75(2):439-44. PubMed ID: 19819536
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy.
Hong SK; Park HZ; Lee WK; Kim DS; Lee JS; Doo SH; Jeong SJ; Yoon CY; Byun SS; Lee SE
Urology; 2010 Sep; 76(3):723-7. PubMed ID: 20579699
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
[TBL] [Abstract][Full Text] [Related]
12. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2010 Jun; 105(11):1541-7. PubMed ID: 19912191
[TBL] [Abstract][Full Text] [Related]
13. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?
Nielsen ME; Makarov DV; Humphreys E; Mangold L; Partin AW; Walsh PC
Urology; 2008 Aug; 72(2):389-93; discussion 394-5. PubMed ID: 18279937
[TBL] [Abstract][Full Text] [Related]
14. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.
King CR; Freedland SJ; Terris MK; Kane CJ; Amling CL; Aronson WJ; Presti JC
Urology; 2007 May; 69(5):921-6. PubMed ID: 17482935
[TBL] [Abstract][Full Text] [Related]
15. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.
Witherspoon LR; Lapeyrolerie T
J Urol; 1997 Apr; 157(4):1322-8. PubMed ID: 9120931
[TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males.
Kinoshita H; Kamoto T; Nishiyama H; Nakamura E; Matsuda T; Ogawa O
Int J Urol; 2007 Oct; 14(10):930-4; discussion 934. PubMed ID: 17880291
[TBL] [Abstract][Full Text] [Related]
17. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
[TBL] [Abstract][Full Text] [Related]
18. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
[TBL] [Abstract][Full Text] [Related]
19. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
Shimizu F; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M
Urol Int; 2007; 79(4):356-60. PubMed ID: 18025856
[TBL] [Abstract][Full Text] [Related]
20. [PSA and follow-up after treatment of prostate cancer].
Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
